MX2022016516A - Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. - Google Patents

Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.

Info

Publication number
MX2022016516A
MX2022016516A MX2022016516A MX2022016516A MX2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A
Authority
MX
Mexico
Prior art keywords
sup
exhibitng
diones
pyridine
mnk
Prior art date
Application number
MX2022016516A
Other languages
English (en)
Spanish (es)
Inventor
Theodore J Price
James J Sahn
Original Assignee
4E Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4E Therapeutics Inc filed Critical 4E Therapeutics Inc
Publication of MX2022016516A publication Critical patent/MX2022016516A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2022016516A 2020-06-30 2021-06-30 Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. MX2022016516A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (1)

Publication Number Publication Date
MX2022016516A true MX2022016516A (es) 2023-03-28

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016516A MX2022016516A (es) 2020-06-30 2021-06-30 Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.

Country Status (11)

Country Link
US (1) US20230286983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533616A (cg-RX-API-DMAC7.html)
KR (1) KR20230041715A (cg-RX-API-DMAC7.html)
CN (1) CN116194112A (cg-RX-API-DMAC7.html)
AU (1) AU2021300363A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026275A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183551A1 (cg-RX-API-DMAC7.html)
IL (1) IL299512A (cg-RX-API-DMAC7.html)
MX (1) MX2022016516A (cg-RX-API-DMAC7.html)
WO (1) WO2022006331A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4363419A4 (en) * 2021-06-30 2025-06-11 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
RU2014111055A (ru) * 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法
JP2018531266A (ja) * 2015-10-22 2018-10-25 セルビタ エス.エー. ピリドン誘導体およびキナーゼ阻害剤としてのその使用
CA3002558A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドSouth Australian Health And Medical Research Institute Limited 高脂肪食関連疾患を阻害する方法
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3870178A4 (en) * 2018-10-24 2022-08-03 Effector Therapeutics Inc. Crystalline forms of mnk inhibitors
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Also Published As

Publication number Publication date
CA3183551A1 (en) 2022-01-06
WO2022006331A9 (en) 2022-03-03
KR20230041715A (ko) 2023-03-24
WO2022006331A3 (en) 2022-02-10
JP2023533616A (ja) 2023-08-03
WO2022006331A8 (en) 2023-03-16
EP4171565A4 (en) 2024-11-27
US20230286983A1 (en) 2023-09-14
EP4171565A2 (en) 2023-05-03
CN116194112A (zh) 2023-05-30
WO2022006331A2 (en) 2022-01-06
BR112022026275A2 (pt) 2023-03-14
AU2021300363A1 (en) 2023-02-09
IL299512A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2024000028A (es) Piridin-1,5-dionas espirocíclicas que exhiben inhibición de la proteína cinasa activada por mitógenos (mnk) y su método de uso.
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
CR20200503A (es) Inhibidores de cinasa dependientes de ciclina
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022008066A (es) Compuestos triciclicos sustituidos.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12021552482A1 (en) Compounds targeting prmt5
PH12022553024A1 (en) Inhibitors of nek7 kinase
MX418519B (es) Inhibidores selectivos de jak1
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
PH12023552774A1 (en) Nek7 inhibitors
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
WO2022006331A8 (en) Pyridine-1,5-diones exhibiting mnk inhibition and their method of use
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
PH12021552513A1 (en) Pyrrole compounds
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2025008428A (es) Derivados de piperidina como inhibidores de mettl3
MX2024002409A (es) Terapias contra el cancer.
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno